2021
DOI: 10.3390/cancers13205181
|View full text |Cite
|
Sign up to set email alerts
|

Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T

Abstract: Non-Hodgkin Lymphoma accounts for >460,000 cases and >240,000 deaths globally and >77,000 cases and >20,000 deaths in the U.S. annually, with ~85% of cases being B-cell malignancies. Until recently, patients with relapsed/refractory B-cell lymphoma following standard chemotherapy in combination with anti-CD20 monoclonal antibodies and autologous stem cell transplantation experienced a median overall survival (OS) of <6 months. However, with the approval of four different CD-19 CAR-T therapies be… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(10 citation statements)
references
References 69 publications
0
10
0
Order By: Relevance
“…[87][88][89] Notwithstanding these biosafety concerns, more than a thousand patients with incurable oncologic diseases have been successfully treated with CAR-T cells. [90,91] To date, not a single clinical report has described proliferative abnormalities that could be attributed to the inadvertent contamination of therapeutic T-cells with VL30 genomes. [38,40,91] Theoretically, it is remotely possible that in contrast to the PG13 producer cells characterized in this study, specific vector producer cell clones that were individually isolated for specific clinical applications did not secrete VL30 genomes-comprising g-retroviral particles.…”
Section: Discussionmentioning
confidence: 99%
“…[87][88][89] Notwithstanding these biosafety concerns, more than a thousand patients with incurable oncologic diseases have been successfully treated with CAR-T cells. [90,91] To date, not a single clinical report has described proliferative abnormalities that could be attributed to the inadvertent contamination of therapeutic T-cells with VL30 genomes. [38,40,91] Theoretically, it is remotely possible that in contrast to the PG13 producer cells characterized in this study, specific vector producer cell clones that were individually isolated for specific clinical applications did not secrete VL30 genomes-comprising g-retroviral particles.…”
Section: Discussionmentioning
confidence: 99%
“…Notwithstanding these biosafety concerns, more than a thousand patients with incurable oncologic diseases have been successfully treated with CAR-T cells [ 94 , 95 ]. To date, not a single clinical report has described proliferative abnormalities that could be attributed to the inadvertent contamination of therapeutic T-cells with VL30 genomes [ 42 , 44 , 95 ].…”
Section: Discussionmentioning
confidence: 99%
“…Thus, there is a possibility that CAR-T cell activation (via the CAR CD28-costimulatory domain) may be altered following binding/sequestration of nuclear PFS by VL30 mRNA [91][92][93]. Notwithstanding these biosafety concerns, more than a thousand patients with incurable oncologic diseases have been successfully treated with CAR-T cells [94,95]. To date, not a single clinical report has described proliferative abnormalities that could be attributed to the inadvertent contamination of therapeutic T-cells with VL30 genomes [42,44,95].…”
Section: Discussionmentioning
confidence: 99%
“…The advent of CAR-T cell therapies has dramatically improved outcomes in the relapsed/refractory setting of several lymphoma subtypes. However, refractoriness to CAR-T treatment, relapse after initial response, therapy-related toxicities, and treatment costs represent relevant hurdles to overcome (34). Therefore, several research fields are being developed towards different aims: to identify strategies to increase CD-19 CAR-T activity and persistence, to target new antigens in B-cell neoplasms, and to identify alternative platforms for CAR engineering.…”
Section: Future Of Car Technologymentioning
confidence: 99%